Yes, Avapritinib, marketed under the brand name Ayvakit, is FDA approved. The U.S. Food and Drug Administration (FDA) approved Avapritinib on January 9, 2020, for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.
Avapritinib is a medication used to treat certain types of cancers and rare blood disorders. It belongs to the class of drugs known as multikinase inhibitors. The drug is administered orally in tablet form and is available in various dosages, including 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg.
Avapritinib can cause several side effects, some of which can be serious. Common side effects include:
Serious side effects that require immediate medical attention include severe headaches, vision problems, changes in mood or behavior, speech difficulties, confusion, hallucinations, severe drowsiness, trouble sleeping, and significant weakness on one side of the body.
Avapritinib should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. It should be stored at room temperature, away from moisture and heat.
Avapritinib (Ayvakit) is an FDA-approved medication effective in treating certain types of cancer and systemic mastocytosis. Approved on January 9, 2020, it offers targeted treatment for patients with specific genetic markers, providing a valuable option for managing these challenging conditions. Patients should consult their healthcare provider to determine if Avapritinib is suitable for their treatment regimen.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!